In recent weeks of May 2022 monkeypox cases have been reported globally; with confirmed cases concentrated in Europe and the US. The identification of confirmed and suspected cases of monkeypox with no direct travel links to an endemic area represents a highly unusual event. With an incubation period of 10 to 14 days many more cases can be expected over the weeks and months. Despite mild disease progression in most healthy individuals symptoms can be severe in immunocompromised patients, children, and pregnant women. There are no therapeutics, and early detection of infection becomes crucial for containment.
Modified Vaccinia Ankara (MVA), manufactured as a smallpox vaccine, provides protection against monkeypox. However, cross-protective immunity from smallpox vaccination will be limited to older persons, since populations under the age of 40 or 50 years no longer benefit from the protection afforded by prior smallpox vaccination campaigns.
The Native Antigen Company have moved to develop a series of antigens to support research into this disease. Four core proteins P4A, P4B, VP8 and 39kDa protein, and the major envelope protein F13L are now in early development, and will be commercially available in the summer of 2022.
Please contact us to register your interest and book pre-release orders.